CAH Stock Recent News

I present 63 high-quality dividend growth stocks for investment for May 2025, categorized by yield: High (4%+), Medium (2.5-3.9%), and Low (

Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio , May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2025 Advanced Therapies Report: Revolutionizing patient care – the promise and potential of cell and gene therapies, providing insights into the evolving landscape of cell and gene therapies (CGTs). This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights into the state of the CGT industry.

DUBLIN, Ohio , May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Industrial engineering company Parker-Hannifin announced its latest payout boost, becoming one of less than a handful of companies with a 70-year dividend growth streak. Investors can expect modest increases from several companies in the first half of May, including a 10% increase from defense company Northrop Grumman.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Burn Care Market, valued at US$2.46 billion in 2024, is forecasted to grow at a robust CAGR of 5.6%, reaching US$2.55 billion in 2025 and an impressive US$3.35 billion by 2030. This market is experiencing consistent growth due to several key factors. The number of burn injuries is rising due to factors such as industrial accidents, domestic fires, and other hazards. Furthermore, advancements in treatment technologies and increased awareness and education about burn care contribute to this trend. Additionally, supportive government initiatives play a significant role in market development. The demand for effective burn treatments is rising as the global population ages. Older individuals are more susceptible to slow-healing wounds and burn complications, which, in turn, increases the need for advanced burn care products. Moreover, technological advancements in burn treatment—including innovative burn dressings, biologics, and

Cardinal Health Inc. CAH on Thursday reported third-quarter 2025 adjusted EPS of $2.35, up 13% year over year, beating the consensus of $2.17.

Cardinal Health, Inc. (NYSE:CAH ) Q3 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Allen Lutz - Bank of America Joanna Dynak - Evercore Eric Percher - Nephron Michael Cherny - Leerink Partners Kevin Caliendo - UBS George Hill - Deutsche Bank Eric Coldwell - Baird Erin Wright - Morgan Stanley Daniel Grosslight - Citi Charles Rhyee - TD Cowen Steve Baxter - Wells Fargo Brian Tanquilut - Jefferies Steven Valiquette - Mizuho Operator Hello, and welcome to the Third Quarter Fiscal Year 2025 Cardinal Health Incorporated Earnings Conference Call. My name is George, and I'll be the coordinator for today's event.

Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.